News

Bio-Techne Announces Schedule for Upcoming Investor Events

Bio-Techne Announces Schedule for Upcoming Investor Events

Bio-Techne to Present at Major Investor Conferences

Exciting news is on the horizon for Bio-Techne Corporation (NASDAQ: TECH) as it reveals its participation in key investor conferences. This is a fantastic opportunity for stakeholders to gain insights into the company’s innovations and future directions.

List of Upcoming Conferences

Bio-Techne is scheduled to present at the following notable investor gatherings:

Annual Evercore Healthcare Conference

Taking place on December 2, 2025, this annual event promises deep insights into healthcare advancements, with Bio-Techne slated to present at 8:20 AM EST.

Citi's Global Healthcare Conference

On December 3, 2025, at 3:15 PM EST, Bio-Techne will engage with investors and analysts during this globally recognized event focused on healthcare innovation.

Nasdaq Investor Conference

Wrapping up the series of presentations, Bio-Techne will be featured at the 53rd Annual Nasdaq Investor Conference on December 9, 2025, at 9:30 AM GMT, where it will discuss its impactful contributions to life sciences.

Webcast Availability

For those interested in following along, a live webcast of the presentations will be readily accessible through the investor relations section of Bio-Techne’s website.

About Bio-Techne Corporation

Bio-Techne Corporation, listed under NASDAQ: TECH, is a leading innovator in the life sciences field. The company is dedicated to providing advanced tools and bioactive reagents for both research and clinical diagnostics. Bio-Techne plays a vital role in enhancing scientific understanding of biological processes and disease progression. Its extensive range of products significantly supports drug discovery initiatives and clinical testing accuracy. In the recent fiscal year, Bio-Techne achieved over $1.2 billion in net sales and employs around 3,100 individuals globally, reflecting its significant impact in the life sciences sector.

Explore More

For further details regarding Bio-Techne and its extensive array of offerings, individuals can visit the official Bio-Techne website. The company actively shares its updates and insights through various social media platforms, including LinkedIn, X, and YouTube, where followers can learn more about its groundbreaking work in life sciences.

Contact Information

For inquiries, please reach out to David Clair, who serves as the Vice President of Investor Relations and Corporate Development at Bio-Techne. His dedication contributes to enhancing investor communications and engagement.

Frequently Asked Questions

What is Bio-Techne Corporation known for?

Bio-Techne is recognized for its innovative tools and bioactive reagents that support research and clinical diagnostics in life sciences.

When will Bio-Techne present at the investor conferences?

Bio-Techne is scheduled to present on December 2, 3, and 9 across different healthcare conferences in 2025.

How can I access the presentations?

The presentations will be available via a live webcast on Bio-Techne's Investor Relations website.

What is the financial performance of Bio-Techne?

In the last fiscal year, Bio-Techne generated over $1.2 billion in net sales, a testament to its industry standing.

Who should I contact for more information about Bio-Techne?

David Clair, the Vice President of Investor Relations & Corporate Development, is the contact for further inquiries about Bio-Techne.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles